UNSPSC 51373467: Guaifenesin/hydrocodone/phenylpropanolamine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373467 Guaifenesin/hydrocodone/phenylpropanolamine/salicylamide is a Commodity code that in practice captures a narrow slice of pharmaceutical procurement by state and local health and correctional agencies. The Washington State Department of Corrections RFQQ RFQQK13020, posted September 8, 2026 with response due October 7, 2026, requests parenteral products and services—including total parenteral nutrition solutions, intravenous fluids, and controlled substances—to supply eight correctional facilities across Washington state. The solicitation does not reflect the code's nominal active pharmaceutical ingredients; instead, DOC is buying a service-intensive product category requiring documented experience in IV solution preparation, patient lab monitoring, and same-day delivery logistics with strict timelines (24 hours for PN bags, 8 hours for other parenteral products). The issuing body is a state correctional agency with set-aside targets for small business (25%), minority-owned business (10%), women-owned business (6%), and veteran-owned business (5%), enforcing a Subcontractor Inclusion Plan for prime contractors and requiring Washington State business licensure and NCIC clearance for all service personnel. A second opportunity, Seminole County, Florida IFB 60459723LAS, posted June 30, 2026 with response due July 26, 2026, requests 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, a pharmaceutical product line unrelated to the code's nominal scope and suggesting a mismatch between the code assignment and the actual procurement.

The code shows minimal recent activity and does not align clearly with state and local procurement patterns. The Washington opportunity dominates the recent record and represents a specialized correctional-healthcare-supply niche rather than a consumer or institutional pharmaceutical category. Geographic representation is limited to Washington state for relevant recent solicitations, with the Seminole County opportunity representing a separate product line (naloxone) that diverges from the code's stated ingredients. The mismatch between the code name and the work being solicited—parenteral products and drug-deactivation supplies rather than the specific pharmaceutical combination the code names—signals either inconsistent code assignment in the state and local system or underutilization of this Commodity code for its intended scope. Firms pursuing this code should focus on correctional-system parenteral supply and infusion services, where the Washington DOC contract shows active demand, rather than rely on the code's nominal pharmaceutical formula.